Picture of Helix Biopharma logo

HBP Helix Biopharma Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareAdventurousMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m-1.36%
3m-8.75%
6m+20.39%
1yr-11.22%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-13.33%
50d MA-1.71%
200d MA+7.8%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equity-2220.98%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Jul 202431st Jul 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Helix Biopharma EPS forecast chart

Profile Summary

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonium and hydroxyl ions. By doing so at the site of cancerous tissues in the body, DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. Its pipeline includes L-DOS47 monotherapy NSCLC, L-DOS47 combo PEM/CARBO NSCLC, L-DOS47 DOXO combo Pancreas, and L-DOS47 combo Immune Checkpoints.

Directors

Last Annual
July 31st, 2023
Last Interim
April 30th, 2024
Incorporated
April 30th, 2008
Public Since
June 3rd, 1996
No. of Employees
9
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconToronto Stock Exchange
Shares in Issue
49,021,550

HBP Share Price Performance

Upcoming Events for HBP

Q4 2024 Helix Biopharma Corp Earnings Release

Q1 2025 Helix Biopharma Corp Earnings Release

Helix Biopharma Corp Annual Shareholders Meeting

Similar to HBP

Picture of Appili Therapeutics logo

Appili Therapeutics

ca flag iconToronto Stock Exchange

Picture of Avicanna logo

Avicanna

ca flag iconToronto Stock Exchange

Picture of Briacell Therapeutics logo

Briacell Therapeutics

ca flag iconToronto Stock Exchange

Picture of Cardiol Therapeutics logo

Cardiol Therapeutics

ca flag iconToronto Stock Exchange

Picture of COSCIENS Biopharma logo

COSCIENS Biopharma

ca flag iconToronto Stock Exchange

FAQ